# Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC

Source: https://onco.cc/trials/nct07596290/  
OnCo record `nct07596290` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial in colorectal cancer, run by Beijing Friendship Hospital, not yet recruiting.

## Summary

Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC is a phase 2/3, randomised interventional study registered as NCT07596290 by Beijing Friendship Hospital, with a registry enrolment figure of 342 participants, started 2026-07-15 and due to reach its primary completion in 2028-12-31. Interventions recorded: Short-course radiotherapy; Long-course radiotherapy; Immunotherapy. Conditions listed: Locally Advanced Rectal Adenocarcinoma; Neoadjuvant Chemoradiation; Neoadjuvant Immunotherapy. Primary outcome: Complete response. Colorectal eligibility wording from the registry: "Histopathologically confirmed rectal adenocarcinoma via colonoscopy; pMMR or MSS phenotype;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Also known as: RADICAL
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07596290
- Phase: 2/3
- Setting: Efficacy and Safety of Neoadjuvant Short-Course/Long-Course Radiotherapy Combined With Anti-PD-1/CTLA-4 Dual Immunotherapy for Locally Advanced Rectal Cancer: A Prospective, Randomized Controlled Trial (RADICAL Trial)
- Sponsor: Beijing Friendship Hospital
- Enrolled: 342

## Sources

- ClinicalTrials.gov NCT07596290: https://clinicaltrials.gov/study/NCT07596290

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07596290.json